+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetic Macular Edema Treatment Market - Global Forecast 2026-2032- Product Image
Diabetic Macular Edema Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Diabetic Macular Edema Treatment Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888142
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Diabetic Macular Edema Treatment Market is projected to reach USD 5.91 Billion in 2026. It is expected to continue growing at a CAGR of 3.41%, reaching USD 7.26 Billion by 2032.

Diabetic Macular Edema Treatment: Executive Overview

Diabetic macular edema (DME) is a vision-threatening complication of diabetes in which retinal fluid accumulation can impair central vision. Treatment pathways typically combine intravitreal pharmacotherapy, laser-based interventions, corticosteroid options, and supportive diabetes and blood-pressure management. Clinical decision-making depends on retinal findings, visual acuity, disease duration, prior treatment, adherence, and access to specialist care.

Treatment Is Shifting Toward Personalized, Durable Care

The treatment landscape is moving beyond a single first-line approach toward individualized care pathways. Clinicians increasingly consider treatment burden, injection frequency, response durability, ocular and systemic risk, and the feasibility of monitoring. Earlier detection through retinal imaging and coordinated diabetes care is also becoming more important, while persistent barriers include delayed referral, inconsistent follow-up, affordability, and uneven access to retinal specialists.

Artificial Intelligence Strengthens Detection and Treatment Monitoring

Artificial intelligence is being applied to diabetic retinopathy and DME screening, image triage, referral prioritization, and longitudinal monitoring. Automated analysis of fundus photography and optical coherence tomography may help identify patients requiring specialist assessment and support more consistent documentation of fluid and structural changes. Clinical validation, data quality, regulatory oversight, explainability, cybersecurity, and integration with clinical workflows remain essential before AI can safely influence treatment decisions.

Regional Differences Reflect Access, Screening, and Care Infrastructure

North America generally benefits from advanced retinal imaging, specialist networks, and established intravitreal treatment pathways, although affordability and continuity of care remain concerns. Europe combines strong clinical expertise with variation in reimbursement, referral systems, and national guidelines. Asia-Pacific spans highly developed ophthalmic systems alongside substantial unmet needs linked to diabetes prevalence, urban-rural disparities, and specialist shortages. Latin America faces uneven screening and treatment access, with care concentrated in major urban centers. The Middle East is expanding diabetes and eye-care capacity but experiences differences in referral and reimbursement systems. Africa continues to face major challenges in screening coverage, specialist availability, diagnostic equipment, and treatment continuity.

Economic and Policy Groups Show Divergent Care Priorities

ASEAN countries are balancing rapid diabetes growth with varied specialist capacity, reimbursement, and rural access. BRICS members reflect broad differences in public-sector coverage, diagnostic infrastructure, and treatment affordability. The European Union benefits from collaborative clinical standards while retaining national differences in reimbursement and service organization. G7 health systems generally have mature ophthalmic capabilities but continue to address aging populations, workforce pressures, and treatment burden. GCC countries are investing in modern diabetes and ophthalmology services, with access differing across health systems and resident populations. NATO members span diverse national models, making interoperability, cross-border evidence, and equitable access recurring policy considerations.

Country-Level Priorities Range from Innovation to Basic Access

Australia and Canada emphasize specialist-led care across geographically dispersed populations. Brazil, Mexico, India, China, and Russia must address scale, regional inequality, and continuity of treatment. France, Germany, Italy, Spain, and the United Kingdom have established retinal services while navigating reimbursement, waiting times, and workforce capacity. Japan and South Korea combine advanced imaging and ophthalmic expertise with the needs of aging populations and long-term diabetes management. The United States has broad access to sophisticated therapies and diagnostics, but insurance complexity, affordability, and adherence remain important barriers.

Industry Leaders Should Reduce Treatment Burden and Expand Earlier Detection

Leaders should prioritize durable treatment strategies, patient-centered scheduling, and evidence that reflects real-world adherence. Partnerships with diabetes-care providers can improve referral and follow-up, while teleophthalmology and validated AI tools may extend screening capacity in underserved settings. Investment should also target interoperable imaging systems, clinician training, affordability programs, and outcome tracking across diverse populations. Any technology deployment should include prospective validation, transparent performance monitoring, privacy safeguards, and clear escalation pathways to ophthalmologists.

Methodology: Evidence-Based Synthesis of Clinical and Health-System Factors

This executive summary uses the supplied market scope-diabetic macular edema treatment-and synthesizes established clinical, technological, and health-system themes. The assessment considers treatment modalities, diagnostic imaging, care delivery, access conditions, regional context, economic groupings, and country-level infrastructure. It deliberately excludes market estimates, market sizing, market shares, forecasts, and company-specific assessments. Interpretations should be read alongside current clinical guidelines, peer-reviewed evidence, regulatory decisions, and locally applicable reimbursement policies.

Conclusion: Better Outcomes Depend on Integrated, Equitable Care

DME treatment is increasingly defined by personalization, monitoring quality, durability, and integration with broader diabetes management. Progress will depend not only on therapeutic innovation but also on earlier detection, reliable referral, sustained follow-up, and equitable access to retinal expertise. Health systems and industry participants that combine validated digital tools with clinically governed care pathways will be better positioned to reduce preventable vision loss while addressing the practical burdens faced by patients and providers.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Diabetic Macular Edema Treatment Market, by Treatment Type
7.1. Introduction
7.2. Pharmacological Treatment
7.3. Laser Therapy
7.4. Surgical Treatment
8. Diabetic Macular Edema Treatment Market, by Drug Class
8.1. Introduction
8.2. Anti-VEGF Agents
8.3. Corticosteroids
9. Diabetic Macular Edema Treatment Market, by Disease Severity
9.1. Introduction
9.2. Mild
9.3. Moderate
9.4. Severe
10. Diabetic Macular Edema Treatment Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Specialty Clinics
11. Diabetic Macular Edema Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Diabetic Macular Edema Treatment Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. Europe
12.4. North America
12.5. Latin America
12.6. Africa
12.7. Middle East
13. Diabetic Macular Edema Treatment Market, by Group
13.1. Introduction
13.2. NATO
13.3. G7
13.4. BRICS
13.5. European Union
13.6. ASEAN
13.7. GCC
14. Diabetic Macular Edema Treatment Market, by Country
14.1. Introduction
14.2. China
14.3. United States
14.4. Japan
14.5. India
14.6. Germany
14.7. United Kingdom
14.8. Australia
14.9. France
14.10. South Korea
14.11. Italy
14.12. Canada
14.13. Russia
14.14. Brazil
14.15. Mexico
14.16. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Adverum Biotechnologies, Inc.
16.3. Aerpio Pharmaceuticals, Inc.
16.4. Alimera Sciences, Inc.
16.5. Astellas Pharma Inc.
16.6. Bayer AG
16.7. Biocon Biologics Ltd.
16.8. Chugai Pharmaceutical Co., Ltd.
16.9. Formycon AG
16.10. Genentech, Inc.
16.11. Kiora Pharmaceuticals, Inc.
16.12. Kodiak Sciences Inc.
16.13. Novartis AG
16.14. Oculis Holding AG
16.15. Outlook Therapeutics, Inc.
16.16. Oxurion NV
16.17. Regeneron Pharmaceuticals, Inc.
16.18. REGENXBIO Inc.
16.19. Roche Holding AG
16.20. Samsung Bioepis Co., Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Diabetic Macular Edema Treatment Market, Years Considered for the Study
FIGURE 2. Global Diabetic Macular Edema Treatment Market, Research Design
FIGURE 3. Global Diabetic Macular Edema Treatment Market, Research Framework
FIGURE 4. Global Diabetic Macular Edema Treatment Market, Data Triangulation
FIGURE 5. Global Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 7. Global Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Diabetic Macular Edema Treatment Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 9. Global Diabetic Macular Edema Treatment Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2025 vs 2032 (%)
FIGURE 11. Global Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Diabetic Macular Edema Treatment Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Diabetic Macular Edema Treatment Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Diabetic Macular Edema Treatment Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Diabetic Macular Edema Treatment Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Diabetic Macular Edema Treatment Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Diabetic Macular Edema Treatment Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Diabetic Macular Edema Treatment Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Diabetic Macular Edema Treatment Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Diabetic Macular Edema Treatment Market Segmentation & Coverage
TABLE 2. Global Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 3. Global Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 4. Global Pharmacological Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Pharmacological Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Pharmacological Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Laser Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Laser Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Laser Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Surgical Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Surgical Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Surgical Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 14. Global Anti-VEGF Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Anti-VEGF Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Anti-VEGF Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 21. Global Mild Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Mild Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Mild Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Moderate Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Moderate Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Moderate Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Severe Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Severe Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Severe Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 31. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 38. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Diabetic Macular Edema Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Asia-Pacific Diabetic Macular Edema Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Asia-Pacific Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 47. Asia-Pacific Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 48. Asia-Pacific Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 49. Asia-Pacific Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 50. Asia-Pacific Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 51. Europe Diabetic Macular Edema Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Europe Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 53. Europe Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 54. Europe Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 55. Europe Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 56. Europe Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 57. North America Diabetic Macular Edema Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. North America Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 59. North America Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 60. North America Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 61. North America Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 62. North America Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 63. Latin America Diabetic Macular Edema Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Latin America Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 65. Latin America Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 66. Latin America Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 67. Latin America Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 68. Latin America Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 69. Africa Diabetic Macular Edema Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Africa Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 71. Africa Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 72. Africa Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 73. Africa Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. Africa Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 75. Middle East Diabetic Macular Edema Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Middle East Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 77. Middle East Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 78. Middle East Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 79. Middle East Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 80. Middle East Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 81. Global Diabetic Macular Edema Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. NATO Diabetic Macular Edema Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. NATO Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 84. NATO Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 85. NATO Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 86. NATO Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. NATO Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. G7 Diabetic Macular Edema Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. G7 Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 90. G7 Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 91. G7 Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 92. G7 Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 93. G7 Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 94. BRICS Diabetic Macular Edema Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. BRICS Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 96. BRICS Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 97. BRICS Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 98. BRICS Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. BRICS Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 100. European Union Diabetic Macular Edema Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. European Union Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 102. European Union Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 103. European Union Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 104. European Union Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. European Union Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. ASEAN Diabetic Macular Edema Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. ASEAN Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 108. ASEAN Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 109. ASEAN Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 110. ASEAN Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. ASEAN Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 112. GCC Diabetic Macular Edema Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. GCC Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 114. GCC Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 115. GCC Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 116. GCC Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. GCC Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 118. Global Diabetic Macular Edema Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. China Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 120. China Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 121. China Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 122. China Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 123. China Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. China Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 125. United States Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 126. United States Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 127. United States Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 128. United States Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 129. United States Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. United States Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. Japan Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 132. Japan Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 133. Japan Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 134. Japan Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 135. Japan Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. Japan Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 137. India Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 138. India Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 139. India Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 140. India Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 141. India Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. India Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 143. Germany Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 144. Germany Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 145. Germany Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 146. Germany Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 147. Germany Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. Germany Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 149. United Kingdom Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 150. United Kingdom Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 151. United Kingdom Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 152. United Kingdom Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 153. United Kingdom Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. United Kingdom Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. Australia Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 156. Australia Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 157. Australia Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 158. Australia Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 159. Australia Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Australia Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. France Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 162. France Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 163. France Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 164. France Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 165. France Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. France Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. South Korea Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 168. South Korea Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 169. South Korea Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 170. South Korea Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 171. South Korea Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. South Korea Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 173. Italy Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 174. Italy Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 175. Italy Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 176. Italy Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 177. Italy Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. Italy Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 179. Canada Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 180. Canada Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 181. Canada Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 182. Canada Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 183. Canada Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. Canada Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 185. Russia Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 186. Russia Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 187. Russia Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 188. Russia Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 189. Russia Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. Russia Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. Brazil Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 192. Brazil Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 193. Brazil Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 194. Brazil Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 195. Brazil Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. Brazil Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 197. Mexico Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 198. Mexico Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 199. Mexico Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 200. Mexico Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 201. Mexico Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. Mexico Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. Spain Diabetic Macular Edema Treatment Market Size, 2017-2032 (USD Million)
TABLE 204. Spain Diabetic Macular Edema Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 205. Spain Diabetic Macular Edema Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 206. Spain Diabetic Macular Edema Treatment Market Size, by Disease Severity, 2017-2032 (USD Million)
TABLE 207. Spain Diabetic Macular Edema Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Spain Diabetic Macular Edema Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. Global Diabetic Macular Edema Treatment Market Share, by Key Player, 2025
TABLE 210. Global Diabetic Macular Edema Treatment Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • Adverum Biotechnologies, Inc.
  • Aerpio Pharmaceuticals, Inc.
  • Alimera Sciences, Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Biocon Biologics Ltd.
  • Chugai Pharmaceutical Co., Ltd.
  • Formycon AG
  • Genentech, Inc.
  • Kiora Pharmaceuticals, Inc.
  • Kodiak Sciences Inc.
  • Novartis AG
  • Oculis Holding AG
  • Outlook Therapeutics, Inc.
  • Oxurion NV
  • Regeneron Pharmaceuticals, Inc.
  • REGENXBIO Inc.
  • Roche Holding AG
  • Samsung Bioepis Co., Ltd.

Related Topics

Related Reports

Diabetic Macular Edema (DME) - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Diabetic Macular Edema (DME) - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Diabetic Macular Edema (DME) Market Report 2026 - Product Image

Diabetic Macular Edema (DME) Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Diabetic Macular Edema Treatment - Global Strategic Business Report - Product Image

Diabetic Macular Edema Treatment - Global Strategic Business Report

  • Report
  • 218 Pages
  • Global
From
Diabetic Macular Edema Market - A Global and Regional Analysis: Focus on Route of Administration, Distribution Channel, and Region, 2025-2035 - Product Image

Diabetic Macular Edema Market - A Global and Regional Analysis: Focus on Route of Administration, Distribution Channel, and Region, 2025-2035

  • Report
  • Global
From
Non-Infectious Macular Edema Treatment - Global Strategic Business Report - Product Image

Non-Infectious Macular Edema Treatment - Global Strategic Business Report

  • Report
  • 235 Pages
  • Global
From

About the Market

Diabetic Macular Edema (DME) is a common complication of diabetes that affects the macula, the central part of the retina responsible for sharp, central vision. DME is caused by the accumulation of fluid in the macula, leading to swelling and blurred vision. Treatment for DME typically involves the use of Optical Disorders Drugs, such as anti-VEGF agents, corticosteroids, and other drugs. Anti-VEGF agents are the most commonly used drugs for DME, as they can reduce the amount of fluid in the macula and improve vision. Corticosteroids are also used to reduce inflammation and swelling in the macula. Other drugs, such as carbonic anhydrase inhibitors, can also be used to reduce fluid accumulation in the macula. The DME Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Regeneron Pharmaceuticals, Novartis, Allergan, Roche, and Bayer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.